Browse the evidence

High perceived stress is directly and positively associated with severe obesity (BMI ≥ 40 kg/m²) in low-income women, independent of eating behaviors and diet quality.

For low-income women with severe obesity, stress management is likely as critical as diet. Since stress drives obesity through biological pathways (like cortisol) independent of food intake, interventions should prioritize stress coping strategies alongside nutrition education to be effective.

Genetic mutations or activation of the Wnt/β-catenin signaling pathway, specifically involving LGR4, RSPOs, and ZNRF3/RNF43, regulate adipose tissue development and obesity risk by controlling the balance between adipocyte proliferation (hyperplasia) and differentiation (hypertrophy) in a depot-specific manner.

This research suggests that obesity is not just about calories but involves complex genetic signaling (Wnt/β-catenin) that dictates how fat cells grow and store energy. While you cannot change your genetics, understanding this helps explain why fat storage differs by body area (visceral vs. subcutaneous) and why some people are more prone to obesity. Lifestyle interventions remain relevant as they interact with these signaling pathways.

Wnt/β-catenin signaling exerts depot-specific effects on white adipose tissue (WAT), where its activation in adipose precursor cells (APs) promotes proliferation (hyperplasia) in visceral WAT (vWAT) under high-fat diet conditions, while its role in subcutaneous WAT (sWAT) involves promoting differentiation and hypertrophy of mature adipocytes.

Fat storage is not uniform across the body. The Wnt/β-catenin signaling pathway regulates how fat cells grow differently in visceral (abdominal) versus subcutaneous (under skin) areas. High-fat diets trigger this pathway to increase the number of fat cells in the visceral area, which is more metabolically harmful. This explains why visceral fat accumulation is a key risk factor for metabolic diseases.

Mutations in the LGR4 gene, specifically the A750T variant, are associated with increased obesity risk, central obesity, and metabolic complications in humans, and ablation of Lgr4 in mice resists diet-induced obesity by promoting browning of visceral white adipose tissue.

Genetic variations in the LGR4 gene can predispose individuals to central obesity and metabolic issues. In mice, removing this gene prevents obesity by promoting the browning of fat, which burns energy. This suggests that targeting the LGR4 pathway could be a potential therapeutic strategy for treating obesity and its complications.

GLP-1 receptor stimulation reduces alcohol consumption and reward, particularly in individuals with high baseline alcohol intake, by acting on the mesolimbic system.

For individuals with high alcohol consumption, GLP-1 based therapies may reduce the desire to drink by lowering the reward value of alcohol. This effect is most prominent in those who drink heavily. While current approvals are for diabetes/obesity, this mechanism suggests potential future use in alcohol use disorder, particularly for heavy drinkers.

The combination of earplugs, eye masks, and relaxing music significantly improves subjective sleep quality in ICU patients, but does not significantly alter nocturnal melatonin or cortisol levels compared to routine care.

For ICU patients, using earplugs, eye masks, and 30 minutes of relaxing music before bed can help them feel they slept better. However, do not expect this to fix stress hormone levels (cortisol/melatonin), as surgery and medications likely override these biological markers. Ensure patients are comfortable with the devices to avoid refusal.

Short-chain fatty acids (SCFAs) produced by gut microbiota influence host energy homeostasis and adipose storage through multiple mechanisms including GPCR signaling and histone deacetylase inhibition.

Increase your intake of fiber-rich foods (vegetables, fruits, whole grains) to boost SCFA production. This supports gut health and may help regulate energy balance and reduce inflammation.

Dysbiosis and increased gut permeability (leaky gut) contribute to obesity through metabolic endotoxemia and low-grade inflammation.

Focus on reducing inflammation through a balanced diet rich in anti-inflammatory foods. Addressing gut health may help manage obesity-related inflammation.

Deficiency or inhibition of the nuclear receptor RORα protects against diet- and age-induced obesity, hepatosteatosis, and insulin resistance by increasing energy expenditure and suppressing pro-inflammatory gene expression in adipose tissue.

This research highlights RORα as a critical regulator of metabolism. While you cannot change your genetics, the discovery of RORα antagonists suggests that future pharmaceutical interventions could potentially mimic the protective effects seen in RORα-deficient mice, such as improved insulin sensitivity and reduced fat storage, by targeting this specific receptor pathway.

Deficiency or inhibition of the nuclear receptor RORγ1 protects against diet-induced insulin resistance and improves glucose tolerance, potentially through mechanisms distinct from RORα.

This research suggests that modulating RORγ1 activity could be a strategy to improve insulin sensitivity. The paper notes that RORγ1 expression positively correlates with adipocyte size and insulin resistance in humans, implying that inhibiting this receptor might help manage type 2 diabetes risk.

RORs (RORα and RORγ) function as intermediaries linking the circadian clock machinery to the regulation of lipid and glucose metabolism, suggesting that circadian disruption may contribute to metabolic syndrome.

Maintaining a consistent sleep schedule and minimizing nighttime light exposure may support healthy metabolic function by aligning with your body's natural circadian rhythms. This alignment helps regulate genes involved in lipid and glucose metabolism, potentially reducing the risk of metabolic syndrome.

Apigenin, a natural flavonoid, ameliorates obesity-related inflammation and metabolic disorders by acting as a selective PPARγ modulator that promotes M2 macrophage polarization without causing the adverse side effects associated with full PPARγ agonists like rosiglitazone.

Apigenin, a flavonoid found in plants like chamomile and parsley, may help reduce obesity-related inflammation and improve metabolic health by modulating the PPARγ receptor. In mouse studies, it reduced inflammatory markers and improved liver and glucose metrics without the weight gain or bone loss seen with prescription drugs like rosiglitazone. While promising, these results are from animal models, and human dosing/effectiveness remains to be established.

Tree nut consumption does not significantly affect fasting insulin or HOMA-IR levels in individuals with type 2 diabetes, although the trend favors improvement.

While tree nuts help lower blood sugar (HbA1c) in people with diabetes, they may not significantly change insulin resistance markers (HOMA-IR) or fasting insulin levels in the short term. This doesn't mean they aren't beneficial, but it highlights that glycemic control and insulin resistance are distinct metrics.

Suprapharmacologic doses of AAS increase muscle mass and strength in eugonadal men through mechanisms involving androgen receptor upregulation, satellite cell activation, and potentially anticatabolic effects, rather than just increased protein synthesis.

The muscle-building effect of high-dose steroids in healthy men is not fully understood but likely involves increasing the number of androgen receptors and activating satellite cells, rather than just speeding up protein synthesis.

Caffeine ingestion (5 mg/kg) does not improve maximal anaerobic power or capacity during the Wingate Test in untrained subjects, despite increasing catecholamine and lactate levels.

If you are not a trained athlete, taking 5mg/kg of caffeine before a short, high-intensity effort (like a 30-second sprint) is unlikely to improve your performance. While it will increase your stress hormones and lactate, it won't make you faster or stronger in that specific context.

Anti-obesity medications targeting monoamine neurotransmitters (re-uptake inhibitors and releasing agents) have a negative benefit-to-harm balance, leading to widespread post-marketing withdrawal due to cardiotoxicity, psychiatric disturbances, and drug abuse.

Avoid centrally acting anti-obesity medications that target monoamine neurotransmitters (e.g., amphetamines, SSRIs used for weight loss) due to high risks of heart problems, psychiatric issues, and addiction. These drugs have been largely withdrawn from the market for these reasons. Focus on diet and lifestyle changes instead, as pharmacological shortcuts have proven unsafe.

Advanced stages of MASLD (fibrosis/MASH) causally contribute to heart failure with preserved ejection fraction (HFpEF) through mechanical impediments to hepatic blood flow, reducing right ventricular preload.

If you have advanced liver fibrosis, monitor for signs of heart failure (fatigue, shortness of breath) even if your heart structure looks normal. The stiffness of your liver can mechanically impede blood flow back to the heart, contributing to HFpEF. Managing liver inflammation may help cardiac preload.

Skeletal muscle-derived myonectin confers protection against ischemia-reperfusion injury in the heart, as endurance training reduces infarct size in wild-type mice but not in myonectin-deficient mice.

Endurance training likely protects your heart against certain types of injury (like those during surgery or heart attack) through the release of myonectin. However, human blood tests for myonectin are inconsistent, so this is a protective mechanism you gain through consistent training, not something you can easily monitor or supplement.

Leptin promotes esophageal adenocarcinoma progression by acting directly on esophageal epithelial cells to increase proliferation, invasiveness, and migration, while reducing apoptosis.

There is no direct practical intervention for leptin levels in this context, but reducing visceral fat may lower circulating leptin levels, potentially reducing this specific pro-tumorigenic signaling.

Overexpression of the LAT1 transporter in vitro paradoxically decreases protein synthesis levels and BCKDHα protein content.

This finding is from a cell study, not humans, so it doesn't change your training or diet today. However, it suggests that simply having more of a specific transporter (LAT1) doesn't automatically mean your muscles will build more protein. The body has complex regulatory mechanisms that might actually suppress synthesis if certain transporters are overexpressed artificially.

The dual GLP-1/glucagon receptor agonist G49 induces rapid weight loss and metabolic rewiring in diet-induced obese mice by triggering inter-organ crosstalk, specifically white adipose tissue lipolysis, liver ketogenesis/FGF21 release, and subsequent brown adipose tissue activation.

This research suggests that combining GLP-1 and Glucagon receptor activation (like the drug G49) is more effective for weight loss and metabolic health than targeting GLP-1 alone. It works by forcing the body to burn fat (lipolysis) and activate brown fat, mimicking the effects of bariatric surgery. While promising in mice, human clinical data is not yet provided in this paper.

Ingestion of an isonitrogenous non-essential amino acid (NEAA) formulation does not stimulate muscle protein synthesis (MPS) or activate mTOR signaling pathways in skeletal muscle cells, making it an effective non-bioactive control for protein bioactivity studies.

If you are looking to stimulate muscle growth, consuming non-essential amino acids alone will not trigger the muscle-building process, even if you consume the same amount of nitrogen as protein. You need essential amino acids (found in complete proteins or EAA supplements) to activate the signaling pathways (mTOR) required for muscle protein synthesis. Use NEAA as a control or filler, not as the primary driver of muscle growth.

Use of GLP-1 receptor agonists (GLP-1 RAs) significantly reduces the risk of developing lymphedema in patients undergoing axillary lymph node dissection (ALND) for breast cancer, independent of diabetes status.

If you are having breast cancer surgery that involves removing lymph nodes, ask your doctor if GLP-1 RAs (like semaglutide or liraglutide) might help reduce your risk of lymphedema, especially if you have a higher BMI or insulin resistance. The study suggests these drugs may significantly lower the risk, but more research is needed to confirm this.

Implantation of alginate-encapsulated engineered HEKGLP-1 cells in mice, activated by endogenous or exogenous melatonin, produces GLP-1 specifically during the night phase, restoring normoglycemia in type-2 diabetic models.

This research proposes a future therapy where genetically engineered cells are implanted and protected in a capsule. These cells produce the diabetes drug GLP-1 only when melatonin levels are high (at night). Patients could take oral melatonin to control how much GLP-1 is produced, potentially allowing for once-daily dosing instead of weekly injections. This is currently only proven in mice.